[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543857":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":53,"collaborators":57,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":31,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":31,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":31,"overallStatus":36,"whyStopped":31,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Irinotecan liposome injection+ Oxaliplatin +Tegafur","EXPERIMENTAL","Oxaliplatin: 60mg\u002Fm2, d1, ivgtt, 2h; Repeat every 15 days; Irinotecan liposomes: 50mg\u002Fm2, d1, ivgtt, 90min; Repeat every 15 days; Tegafur: 40-60mg, BID, po, d1-d10, repeat every 15 days; 30 days as one cycle, 6 treatment cycles.",[13],"Drug: Irinotecan liposome injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Irinotecan liposome injection","Postoperative adjuvant therapy",[9],[21,22],"oxaliplatin","Tegafur",[24],{"name":25,"affiliation":5,"role":26},"KuiRong Jiang, archiater","PRINCIPAL_INVESTIGATOR",[28],{"name":25,"role":29,"phone":30,"phoneExt":31,"email":32},"CONTACT","15312995688",null,"Jiangkuirong@163.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"FirstNanjingMU","RECRUITING","Nanjing","Jiangsu","025","China","CN",{"type":43,"coordinates":44},"Point",[45,46],118.77778,32.06167,{"lat":46,"lon":45},[49,50],{"name":25,"role":29,"phone":30,"phoneExt":31,"email":32},{"name":51,"role":52,"phone":31,"phoneExt":31,"email":31},"Min Tu, associate doctor","SUB_INVESTIGATOR",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"SPONSOR_INVESTIGATOR","Kuirong Jiang","archiater",[58],{"name":59,"class":60},"CSPC Ouyi Pharmaceutical Co., Ltd.","INDUSTRY","100543857","irinotecan-liposome-combined-with-oxaliplatin-and-tegafur-as-adjuvant-therapy-for-pancreatic-cancer-100543857",false,"NCT06361316","Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer","Efficacy and Safety of Irinotecan Liposome Injection Combined With Oxaliplatin and Tegafur (NASOX) in Adjuvant Chemotherapy for Pancreatic Cancer","Inclusion Criteria:\n\n1. ECOG performance status 0 or 1.\n2. Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1).\n3. ECOG performance status 0 or 1.\n4. Life expectancy of greater than or equal to 6 months.\n5. Able and willing to provide a written informed consent.\n\nExclusion Criteria:\n\n1. Patients who cannot eat orally and have gastric emptying disorder after surgery;\n2. Patients with moderate diarrhea: diarrhea ≥4 times per day; the moderate and severe effluents from stoma increased; Or diarrhea that limits activities of daily living;\n3. Patients who cannot eat orally and have gastric emptying disorder after surgery;\n4. Patients who cannot eat orally and have gastric emptying disorder after surgery;","ALL","18 Years","75 Years",{"count":72,"type":73},53,"ESTIMATED","INTERVENTIONAL",[76],"NA","The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.",[79,80],"Pancreatic Cancer","Adjuvant Therapy","2024-04-08",{"date":83,"type":84},"2024-04-11","ACTUAL",{"date":81,"type":73},{"date":87,"type":73},"2028-07-31",{"name":55,"class":6},1]